Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel inhibitors in the treatment of metastatic melanoma.

Expert review of anticancer therapy - 1 May 2007

Kalinsky Kevin, Haluska Frank G

Abstract excerpt

Metastatic melanoma continues to be a difficult disease to treat. Recent efforts have focused on developing novel, target-directed therapeutic agents. In this review, we discuss the RAS-RAF-MAP kinase and the RAS-PI3K-AKT pathway in detail, as up to 80% of cutaneous melanomas exhibit a BRAF mutation. The preclinical and clinical data regarding BRAF inhibition is reviewed. Other potential targets in these pathways...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to MAP Kinase Signaling System
Share to Melanoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins B-raf

Share to ras Proteins

Share to Skin Neoplasms

Source

Identifiers

PMID: 17492934
DOI: 10.1586/14737140.7.5.715

Genes

BRAF
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel inhibitors in the treatment of metastatic melanoma.PMID 17492934Read ↗

Advances in targeted therapy for melanoma.Semantic proximity Read ↗

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Semantic proximity Read ↗

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read ↗

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.Semantic proximity Read ↗

Molecularly targeted therapies for melanoma.Semantic proximity Read ↗

Targeted therapies for cutaneous melanoma.Semantic proximity Read ↗

Targeting BRAF in melanoma: biological and clinical challenges.Semantic proximity Read ↗

Update on the targeted therapy of melanoma.Semantic proximity Read ↗

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidenceSemantic proximity Read ↗

Novel therapies in melanoma.Semantic proximity Read ↗

New drug targets in metastatic melanoma.Semantic proximity Read ↗

BRAF signaling and targeted therapies in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.